Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15992392 | 1.00 | PPARG (1.00) | PPARGCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15992288 | 1.00 | PPARG (1.00) | PPARGCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4539858 | 0.94 | PPARG (0.89) | PPARGCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4540388 | 0.93 | PPARG (0.87) | PPARGCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15992198 | 0.92 | PPARG (0.86) | PPARGCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16731516 | 0.92 | PPARG (0.86) | PPARGCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16000001 | 0.92 | PPARG (0.86) | PPARGCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16000000 | 0.92 | PPARG (0.86) | PPARGCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15991920 | 0.91 | PPARG (0.84) | PPARGCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15991921 | 0.91 | PPARG (0.84) | PPARGCYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249196-A1 | N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE | 2014-09-04 | — | — | US | disclosed |
| US-20140249196-A1 | N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE | 2014-09-04 | — | — | US | disclosed |
| US-20140249196-A1 | N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE | 2014-09-04 | — | — | US | disclosed |
| WO-2013078233-A1 | N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG | RIPKA AMY S (US) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249196-A1 | N-BENZYLBENZIMIDAZOLE MODULATORS OF PPARG | PPARG, CDK5, CDK5R1 | PPARG 1/4885CYP1A2 3318/4885CYP3A4 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.